Hippocrates Research Swiss offers a boutique CRO model built on 30 years of experience. With a lean, agile structure and senior-level involvement, we transform scientific innovation into strong clinical assets, delivering capital efficiency, strategic focus, and measurable value.

Hemastatx brings innovation to patients with severe, underserved bleeding conditions. HMX-001 is a first-in-class anti-ADAMTS13 antibody targeting the root cause of severe bleeds in (rare) von Willebrand factor (VWF) disorders. Hemastatx is a KU Leuven spinoff and part of the BaseLaunch portfolio.

Biodelphis Therapeutics is a Swiss biotech startup, spinoff of EPFL. We developed a new generation of protease inhibitors with enhanced potency and safety, exhibiting all the qualities needed to become first-in-class drugs for the treatment of cancer, autoimmune diseases and bone diseases.